Cargando…

Why Physical Activity Should Be Considered in Clinical Trials for COVID-19 Vaccines: A Focus on Risk Groups

Since the World Health Organization declared the global COVID-19 state of emergency in early 2020, several vaccine candidates have emerged to control SARS-CoV-2, and some of them have been approved and implemented in vaccination campaigns worldwide. Although clinical trials for these vaccines have b...

Descripción completa

Detalles Bibliográficos
Autores principales: Bortolini, Miguel Junior Sordi, Petriz, Bernardo, Mineo, José Roberto, Resende, Rafael de Oliveira
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8834774/
https://www.ncbi.nlm.nih.gov/pubmed/35162875
http://dx.doi.org/10.3390/ijerph19031853
_version_ 1784649266596151296
author Bortolini, Miguel Junior Sordi
Petriz, Bernardo
Mineo, José Roberto
Resende, Rafael de Oliveira
author_facet Bortolini, Miguel Junior Sordi
Petriz, Bernardo
Mineo, José Roberto
Resende, Rafael de Oliveira
author_sort Bortolini, Miguel Junior Sordi
collection PubMed
description Since the World Health Organization declared the global COVID-19 state of emergency in early 2020, several vaccine candidates have emerged to control SARS-CoV-2, and some of them have been approved and implemented in vaccination campaigns worldwide. Although clinical trials for these vaccines have been carried out using highly controlled methods with accurate immunological tests, clinical questionnaires did not include questions concerning the physical activity profile among volunteers. It has been well established that physical activity plays a pivotal role in the immune response after vaccination, led by the activation of cytokines, antibodies, and cells. This concept should have been considered when evaluating the efficacy of COVID-19 vaccine candidates, particularly in elderly and obese people. Here, we discuss data from the literature providing strong evidence regarding the importance of analyzing physical activity parameters to improve the accuracy of clinical trials on assessing the efficacy of vaccine candidates.
format Online
Article
Text
id pubmed-8834774
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-88347742022-02-12 Why Physical Activity Should Be Considered in Clinical Trials for COVID-19 Vaccines: A Focus on Risk Groups Bortolini, Miguel Junior Sordi Petriz, Bernardo Mineo, José Roberto Resende, Rafael de Oliveira Int J Environ Res Public Health Review Since the World Health Organization declared the global COVID-19 state of emergency in early 2020, several vaccine candidates have emerged to control SARS-CoV-2, and some of them have been approved and implemented in vaccination campaigns worldwide. Although clinical trials for these vaccines have been carried out using highly controlled methods with accurate immunological tests, clinical questionnaires did not include questions concerning the physical activity profile among volunteers. It has been well established that physical activity plays a pivotal role in the immune response after vaccination, led by the activation of cytokines, antibodies, and cells. This concept should have been considered when evaluating the efficacy of COVID-19 vaccine candidates, particularly in elderly and obese people. Here, we discuss data from the literature providing strong evidence regarding the importance of analyzing physical activity parameters to improve the accuracy of clinical trials on assessing the efficacy of vaccine candidates. MDPI 2022-02-07 /pmc/articles/PMC8834774/ /pubmed/35162875 http://dx.doi.org/10.3390/ijerph19031853 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Bortolini, Miguel Junior Sordi
Petriz, Bernardo
Mineo, José Roberto
Resende, Rafael de Oliveira
Why Physical Activity Should Be Considered in Clinical Trials for COVID-19 Vaccines: A Focus on Risk Groups
title Why Physical Activity Should Be Considered in Clinical Trials for COVID-19 Vaccines: A Focus on Risk Groups
title_full Why Physical Activity Should Be Considered in Clinical Trials for COVID-19 Vaccines: A Focus on Risk Groups
title_fullStr Why Physical Activity Should Be Considered in Clinical Trials for COVID-19 Vaccines: A Focus on Risk Groups
title_full_unstemmed Why Physical Activity Should Be Considered in Clinical Trials for COVID-19 Vaccines: A Focus on Risk Groups
title_short Why Physical Activity Should Be Considered in Clinical Trials for COVID-19 Vaccines: A Focus on Risk Groups
title_sort why physical activity should be considered in clinical trials for covid-19 vaccines: a focus on risk groups
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8834774/
https://www.ncbi.nlm.nih.gov/pubmed/35162875
http://dx.doi.org/10.3390/ijerph19031853
work_keys_str_mv AT bortolinimigueljuniorsordi whyphysicalactivityshouldbeconsideredinclinicaltrialsforcovid19vaccinesafocusonriskgroups
AT petrizbernardo whyphysicalactivityshouldbeconsideredinclinicaltrialsforcovid19vaccinesafocusonriskgroups
AT mineojoseroberto whyphysicalactivityshouldbeconsideredinclinicaltrialsforcovid19vaccinesafocusonriskgroups
AT resenderafaeldeoliveira whyphysicalactivityshouldbeconsideredinclinicaltrialsforcovid19vaccinesafocusonriskgroups